文献速递消化道肿瘤与早癌消化内镜

图像增强内镜联合分子生物标志物对比西雅图方案诊断巴雷特食管异型增生

Image-Enhanced Endoscopy and Molecular Biomarkers Vs Seattle Protocol to Diagnose Dysplasia in Barrett's Esophagus.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-02-17

本研究将无可见异型增生病灶的巴雷特食管患者随机交叉分配至高清白光内镜联合西雅图方案活检组或自体荧光成像引导探头共聚焦激光显微内镜联合靶向活检及分子标志物检测组。结果显示两种内镜方法对异型增生的敏感性相似,而分子标志物组合在总体组织学分析中敏感性高于西雅图方案,但在试验组织学分析中差异未达统计学显著。

要点

  • 西雅图方案活检约遗漏一半不显性肿瘤患者的异型增生。
  • 自体荧光成像引导共聚焦内镜与高清白光内镜联合西雅图方案诊断准确性相似。
  • 分子标志物组合在总体组织学分析中敏感性高于西雅图方案,但试验组织学分析未达显著。

核心结论

  • 西雅图方案活检约遗漏一半不显性肿瘤患者的异型增生;自体荧光成像引导共聚焦内镜与当前金标准准确性相似;加入分子生物标志物可能提高诊断准确性。

研究设计与样本

  • 无可见异型增生病灶的巴雷特食管患者被区组随机分配至标准内镜(高清白光内镜联合西雅图方案)或自体荧光成像引导共聚焦内镜联合靶向活检及分子标志物检测,6至12周后交叉至另一组。
  • 共招募154例患者,134例完成两组检查。
  • 主要终点为所有研究活检的组织学诊断(试验组织学);敏感性分析采用总体组织学,包括首次研究内镜后12个月内的诊断。
  • 内镜医师对转诊内镜及组织学结果设盲。

主要发现

  • 主要结局分析(试验组织学分析)中,自体荧光成像引导共聚焦内镜对异型增生的敏感性与标准内镜相似(74.3%;95%CI 56.7-87.5 对比 80.0%;95%CI 63.1-91.6;P=0.48)。
  • 多变量逻辑回归显示,共聚焦内镜光学异型增生、p53异常和异倍体与异型增生相关性最强(次要结局)。
  • 总体组织学分析中,三标志物组合对任何级别异型增生的敏感性高于西雅图方案(81.5% 对比 51.9%;P<0.001)。
  • 试验组织学分析中,三标志物组合对任何级别异型增生的敏感性对比西雅图方案为91.4% 对比 80.0%(P=0.16),未达统计学显著;受试者工作特征曲线下面积为0.83。

关键数值与推荐

  • 自体荧光成像引导共聚焦内镜对异型增生的敏感性为74.3%(95%CI 56.7-87.5),标准内镜为80.0%(95%CI 63.1-91.6),P=0.48。
  • 总体组织学分析中三标志物组合对任何级别异型增生的敏感性为81.5%,西雅图方案为51.9%,P<0.001。
  • 试验组织学分析中三标志物组合对任何级别异型增生的敏感性为91.4%,西雅图方案为80.0%,P=0.16;受试者工作特征曲线下面积为0.83。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Dysplasia in Barrett's esophagus often is invisible on high-resolution white-light endoscopy (HRWLE). We compared the diagnostic accuracy for inconspicuous dysplasia of the combination of autofluorescence imaging (AFI)-guided probe-based confocal laser endomicroscopy (pCLE) and molecular biomarkers vs HRWLE with Seattle protocol biopsies. METHODS: Barrett's esophagus patients with no dysplastic lesions were block-randomized to standard endoscopy (HRWLE with the Seattle protocol) or AFI-guided pCLE with targeted biopsies for molecular biomarkers (p53 and cyclin A by immunohistochemistry; aneuploidy by image cytometry), with crossover to the other arm after 6 to 12 weeks. The primary end point was the histologic diagnosis from all study biopsies (trial histology). A sensitivity analysis was performed for overall histology, which included diagnoses within 12 months from the first study endoscopy. Endoscopists were blinded to the referral endoscopy and histology results. The primary outcome was diagnostic accuracy for dysplasia by real-time pCLE vs HRWLE biopsies. RESULTS: Of 154 patients recruited, 134 completed both arms. In the primary outcome analysis (trial histology analysis), AFI-guided pCLE had similar sensitivity for dysplasia compared with standard endoscopy (74.3%; 95% CI, 56.7-87.5 vs 80.0%; 95% CI, 63.1-91.6; P = .48). Multivariate logistic regression showed pCLE optical dysplasia, aberrant p53, and aneuploidy had the strongest correlation with dysplasia (secondary outcome). This 3-biomarker panel had higher sensitivity for any grade of dysplasia than the Seattle protocol (81.5% vs 51.9%; P < .001) in the overall histology analysis, but not in the trial histology analysis (91.4% vs 80.0%; P = .16), with an area under the receiver operating curve of 0.83. CONCLUSIONS: Seattle protocol biopsies miss dysplasia in approximately half of patients with inconspicuous neoplasia. AFI-guided pCLE has similar accuracy to the current gold standard. The addition of molecular biomarkers could improve diagnostic accuracy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Vithayathil M, Modolell I, Ortiz-Fernandez-Sordo J, et al. Image-Enhanced Endoscopy and Molecular Biomarkers Vs Seattle Protocol to Diagnose Dysplasia in Barrett's Esophagus. Clin Gastroenterol Hepatol. 2022. PMID: 35183768. doi:10.1016/j.cgh.2022.01.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。